Evotec AG today announced that it is adjusting its guidance regarding Group revenues. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-results-of-pre-clinical-studies-lead-to-reduction-in-revenues-nevertheless-profitable-and-more-than-eur-90-m-cash-for-2013-confirmed-5188
Evotec AG: Results of pre-clinical studies lead to reduction in revenues, nevertheless profitable and more than EUR 90 m cash for 2013 confirmed
Evotec AG today announced that it is adjusting its guidance regarding Group revenues. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-ag-results-of-pre-clinical-studies-lead-to-reduction-in-revenues-nevertheless-profitable-and-more-than-eur-90-m-cash-for-2013-confirmed-5612
Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim
Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-pre-clinical-milestone-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-5184
Evotec AG reports first nine months 2013 results
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the third quarter and first nine months of 2013 ending 30 September 2013. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-first-nine-months-2013-results-5183
Evotec announces TargetAD collaboration with Johnson & Johnson Innovation to identify and develop novel Alzheimer's disease therapies
Evotec AG today announced a collaboration with the Johnson & Johnson Innovation Center in California to identify new targets for Alzheimer’s disease drug discovery and development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-targetad-collaboration-with-johnson–johnson-innovation-to-identify-and-develop-novel-alzheimers-disease-therapies-5181
Evotec and The Leukemia & Lymphoma Society enter into a strategic research collaboration
Evotec AG announced today that it has entered into an integrated research collaboration with The Leukemia & Lymphoma Society. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-the-leukemia–lymphoma-society-enter-into-a-strategic-research-collaboration-5177
Evotec achieves first milestones in multi-target deal with UCB
Evotec AG today announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-first-milestones-in-multi-target-deal-with-ucb-5175
Evotec enters integrated alliance with AstraZeneca in kidney disease
Evotec AG today announced that it has signed an agreement with AstraZeneca in the field of kidney diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-integrated-alliance-with-astrazeneca-in-kidney-disease-5173
Evotec publishes DDup 4 – Epigenetics
Evotec AG today announced the publication of its fourth DDup edition. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-4—epigenetics-5170
Evotec to hold R&D Day 2013
Evotec AG announced today that its R&D Day 2013 will take place on 22 October 2013 in New York City, USA. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-hold-rd-day-2013-5169